Absci

Yahoo Finance • yesterday

Absci spikes as J.P. Morgan starts at Buy ahead of key catalyst

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images * Absci (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]) shares traded higher on Thursday after J.P. Morgan initiated its coverage on the AI-driven biotech with a... Full story

Yahoo Finance • 23 days ago

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Absci Corporation; Oracle; AMD Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLO... Full story

Yahoo Finance • last month

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney... Full story

Yahoo Finance • last month

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be par... Full story

Yahoo Finance • 2 months ago

Absci Corp (NASDAQ:ABSI) Q2 2025 Earnings: Revenue Miss Sparks Market Selloff

ABSCI CORP (NASDAQ:ABSI) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, MARKET REACTS NEGATIVELY Absci Corp (NASDAQ:ABSI [https://www.chartmill.com/stock/quote/ABSI]) reported its second-quarter 2025 financial results, revealing a re... Full story

Yahoo Finance • 2 months ago

Absci GAAP EPS of -$0.24 misses by $0.03, revenue of $0.6M misses by $0.61M

* Absci press release [https://seekingalpha.com/pr/20198634-absci-reports-business-updates-and-second-quarter-2025-financial-and-operating-results] (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.24 misses by $0.... Full story

Yahoo Finance • 2 months ago

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration w... Full story

Yahoo Finance • 2 months ago

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spa... Full story

Yahoo Finance • 2 months ago

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will re... Full story

Yahoo Finance • 2 months ago

Cathie Wood's ARK ETF adjusts portfolio, buys ABSCI, sells CRISPR

In the latest trading session, Cathie Wood’s ARK ETFs made several significant transactions as part of their ongoing portfolio adjustments. On Friday, July 25th, 2025, the most substantial trade came from the purchase of 2,248,226 shares o... Full story

Yahoo Finance • 2 months ago

Absci Prices $50 Mln Public Offering To Advance AI-Driven Drug Programs

(RTTNews) - Absci Corporation (ABSI), a clinical-stage biopharma company leveraging generative AI for drug discovery, has priced an underwritten public offering of 16.67 million shares of its common stock at $3.00 per share. The offering... Full story

Yahoo Finance • 2 months ago

Absci announces proposed public offering of common stock

* Absci (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]) on Thursday said it has commenced an underwritten public offering of $50 million of shares of its common stock. * Absci also intends to grant the underwriters a 30-day option... Full story

Yahoo Finance • 2 months ago

Absci Announces Proposed Public Offering of Common Stock

VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it... Full story

Yahoo Finance • 3 months ago

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retire... Full story

Yahoo Finance • 3 months ago

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Absci Corporation Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI),... Full story

Yahoo Finance • 3 months ago

Absci stock rating initiated at Overweight by Morgan Stanley

Investing.com - Morgan Stanley has initiated coverage on Absci Corp. (NASDAQ:ABSI) with an Overweight rating and a $7.00 price target. The company, currently valued at $343 million, has seen its stock demonstrate significant volatility w... Full story

Yahoo Finance • 5 months ago

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and conve... Full story

Yahoo Finance • 6 months ago

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating re... Full story

Yahoo Finance • 7 months ago

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creati... Full story

Yahoo Finance • 7 months ago

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating re... Full story